Indo Us Biotech Limited (INDOUS)

Indo Us Biotech announced that Managing Director cum Promoter Mr. Jagdish Ajudia, Executive Director cum Promoter Mrs. Priyanka Samarth Patel, and Promoter Mr. Samarth Patel received an invitation to attend the 140th China Import and Export Fair (Canton Fair). The trade fair will be held at the China Import and Export Fair Complex in Guangzhou, China. The filing merely discloses the receipt of an event invitation without specifying any business commitments, orders, or commercial deals.

• Promoters received invitation to attend the 140th China Import and Export Fair (Canton Fair)
• Event location: China Import and Export Fair Complex, Guangzhou, China
• Delegation includes 3 promoters: Mr. Jagdish Ajudia (MD), Mrs. Priyanka Samarth Patel (ED), and Mr. Samarth Patel
• Commercial value, tie-ups, or orders from the visit are not disclosed

Indo Us Bio-Tech Limited held its 22nd Annual General Meeting on September 30, 2026, via video conferencing. Key ordinary business items included the adoption of FY2026 audited financial statements, the reappointment of Director Mrs. Priyanka Samarth Patel, and the appointment of Statutory Auditors. Special resolutions regarding the company's borrowing limits and approval of Related Party Transactions under Section 188 were also tabled. Voting results from remote and AGM e-voting are slated to be disclosed within 48 hours.

• 22nd Annual General Meeting conducted electronically on September 30, 2026, lasting 9 minutes (14:30 to 14:39 PM)
• Special business tabled includes approval for Company Borrowing Limits and Related Party Transactions under Section 188
• Ordinary business included adoption of balance sheet as at March 31, 2026, and reappointment of Mrs. Priyanka Samarth Patel
• Final scrutinizer voting report to be submitted to exchanges within 48 hours

Indo Us Biotech Limited has issued notice for its 22nd Annual General Meeting (AGM) scheduled for September 30, 2026, with the register of members closing from September 23 to September 30, 2026. Key special resolutions include enhancing the Board's borrowing limit up to ₹250 Crore over paid-up capital and free reserves, creating asset charges up to ₹100 Crore, and approving related party transactions up to ₹10 Crore per transaction type. The company has also proposed appointing M/s Bhagat & Associates as Statutory Auditors for a 5-year term ending at the 2031 AGM.

• 22nd AGM scheduled for September 30, 2026 via Video Conferencing / OAVM.
• Share transfer books and register of members closed from September 23, 2026 to September 30, 2026.
• Special resolution tabled to approve borrowing limits up to ₹250 Crore over and above paid-up capital and free reserves.
• Approval sought for creating asset charges/mortgages up to ₹100 Crore.
• Related party transactions approval sought under Section 188 up to ₹10 Crore for each transaction type.

Indo Us Biotech Limited has approved the convening of its 22nd Annual General Meeting (AGM) on September 30, 2026, via video conferencing. The Board recommended the appointment of M/s. Bhagat & Associates, Chartered Accountants, as Statutory Auditors for a 5-year term from the conclusion of the 22nd AGM to the 27th AGM, subject to shareholder approval. The record cut-off date for e-voting eligibility is set for September 23, 2026, with the book closure scheduled from September 23 to September 30, 2026.

• 22nd Annual General Meeting scheduled for September 30, 2026 at 02:30 PM
• Recommendation to appoint M/s. Bhagat & Associates as Statutory Auditors for a 5-year tenure
• Remote e-voting window runs from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
• Cut-off date for voting eligibility and book closure start date set as September 23, 2026

Indo Us Biotech Limited has announced the results of its postal ballot concluded on August 3, 2026. Shareholders approved the regularization of Mrs. Hemanshi Darsh Soni as an Independent Director for a five-year term and the appointment of M/s. Bhagat & Associates as Statutory Auditors to fill a casual vacancy. The voting saw a total turnout of 69.76%, driven primarily by 100% promoter participation, while public participation remained low at 4.64%.

• Total of 1,39,88,567 votes were polled, representing 69.76% of the total 2,00,52,000 shares
• Promoter group cast 1,36,93,643 votes, representing 100% of their holding, all in favor of the resolutions
• Mrs. Hemanshi Darsh Soni regularized as Independent Director for a 5-year term effective from April 21, 2026
• Public non-institutional participation was low, with only 2,94,924 shares (4.64% of the category) voting
• M/s. Bhagat & Associates appointed as Statutory Auditors to hold office until the next Annual General Meeting

Indo Us Biotech Limited has submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended June 30, 2026. The company confirmed that while all 6 required events for the current quarter were captured, a technical software failure resulted in the loss of historical SDD records. Management has initiated a Root Cause Analysis (RCA) with the software vendor and implemented new backup and data verification protocols to prevent recurrence. This filing is a mandatory disclosure under SEBI (Prohibition of Insider Trading) Regulations.

• 6 events were required to be captured in the SDD during the quarter, and all 6 were successfully recorded.
• Historical SDD records became unavailable and unretrievable due to an unforeseen technical software issue.
• The company's database is designed to be non-tamperable with a record maintenance capability of 8 years.
• Corrective actions include requesting a Root Cause Analysis (RCA) from the vendor and strengthening internal monitoring controls.

Indo Us Biotech Limited has announced the resignation of its statutory auditor, M/s. Gautam N Associates, effective June 15, 2026. The outgoing auditor cited 'administrative and operational restructuring' as the reason for resignation and confirmed there are no other material concerns. The Board has appointed M/s. Bhagat & Associates as the new statutory auditor, subject to shareholder approval at the next General Meeting. This change follows the previous auditor's re-appointment for a five-year term just months earlier in October 2025.

• M/s. Gautam N Associates resigned as Statutory Auditor effective June 15, 2026
• M/s. Bhagat & Associates appointed as the new auditor by the Board on June 16, 2026
• Outgoing auditor had recently been re-appointed for a 5-year term on October 14, 2025
• Last audit report for FY26 was submitted by the outgoing auditor on May 29, 2026
• Auditor confirmed no inability to obtain audit evidence or management-imposed limitations

Indo Us Biotech Limited has updated the composition of its key board committees effective July 10, 2026. This administrative move follows the appointment of Mrs. Hemanshi Darsh Soni as an Additional Independent Director on April 21, 2026, replacing Mrs. Nehaben Patel. The Audit, Nomination & Remuneration, and Stakeholders Relationship Committees have all been reconstituted to ensure compliance with SEBI (LODR) Regulations. The board meeting was brief, lasting 30 minutes to finalize these governance updates.

• Board meeting held on July 10, 2026, concluded within 30 minutes (15:00 to 15:30).
• Mrs. Hemanshi Darsh Soni (DIN: 11659183) added to 3 major board committees.
• Audit Committee now comprises 4 members, led by Chairperson Ritaben Nileshbhai Kikani.
• Reconstitution follows the director appointment made on April 21, 2026.
• Changes are effective immediately from July 10, 2026, to meet SEBI and Companies Act requirements.

Indo Us Biotech Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar, Bigshare Services Private Limited, confirmed that no securities were received for dematerialization during the quarter from April 1, 2026, to June 30, 2026. As a result, no certificates were mutilated or cancelled, and no names were substituted in the register of members. This filing is a routine regulatory requirement for all listed entities in India.

• Quarterly compliance period ended June 30, 2026
• Zero (0) securities were received from depository participants for dematerialization
• No certificates were mutilated or cancelled during the period from March 31, 2026, to June 30, 2026
• Confirmation provided by Registrar and Share Transfer Agent, Bigshare Services Private Limited

The promoter of Indo Us Biotech Limited, Jagdishkumar Devjibhai Ajudiya, has filed a formal declaration under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The filing confirms that the promoter group holds 1,36,93,643 shares, representing a 68.29% stake in the company. Most importantly, the declaration states that no shares were encumbered or pledged, directly or indirectly, during the entire financial year. This routine disclosure provides transparency regarding the stability of the promoter's equity position.

• Promoter group held 1,36,93,643 shares as of March 31, 2026
• Total promoter stake is confirmed at 68.29% of the company
• Zero (0) shares were encumbered or pledged during the financial year 2025-26
• Promoter holding decreased slightly from 70.18% in December 2025 to 68.29% in March 2026

Indo Us Biotech has issued a postal ballot notice to shareholders for two key resolutions. The company is seeking to regularize the appointment of Mrs. Hemanshi Darsh Soni as an Independent Director for a 5-year term starting April 21, 2026. Additionally, it proposes the appointment of M/s. Bhagat & Associates as Statutory Auditors to fill a casual vacancy following the resignation of the previous auditor. The e-voting process will conclude on August 3, 2026, with results expected by August 5, 2026.

• E-voting period is scheduled from July 5, 2026, to August 3, 2026
• Cut-off date for determining shareholder voting eligibility was June 26, 2026
• Proposed Independent Director term is for 5 years effective from April 21, 2026
• New Statutory Auditor M/s. Bhagat & Associates (FRN: 101100W) to fill casual vacancy until the next AGM

Indo Us Biotech Limited has announced the closure of its trading window for designated persons starting July 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of unaudited financial results for the quarter ending June 30, 2026. The window will remain closed until 48 hours after the results are officially announced. This is a standard procedural requirement for all listed companies and does not indicate any fundamental change in business operations.

• Trading window closure effective from July 1, 2026
• Closure pertains to the financial results for the quarter ending June 30, 2026
• Window to reopen 48 hours after the announcement of unaudited financial results
• Company reported a net profit of ₹2.9966 cr in the Dec 2025 quarter

Indo Us Biotech Limited has announced a change in its statutory auditors effective June 15, 2026. M/s. Gautam N Associates resigned from the position, citing administrative and operational restructuring and the company's desire to appoint an auditor based near its registered office in Ahmedabad for better logistical coordination. Consequently, the Board has approved the appointment of M/s. Bhagat & Associates as the new Statutory Auditor, subject to shareholder approval. The outgoing auditor has confirmed there are no other material reasons for their resignation.

• M/s. Gautam N Associates resigned as Statutory Auditor effective June 15, 2026.
• M/s. Bhagat & Associates (FRN: 101100W) appointed as the new auditor by the Board on June 16, 2026.
• The change is driven by a need for logistical efficiency and local coordination in Ahmedabad.
• Outgoing auditors confirmed no material concerns or disagreements with the management.
• The new appointment is valid until the conclusion of the next General Meeting, pending shareholder approval.

Indo Us Biotech Limited has announced a restructuring of its audit functions by appointing new Statutory and Internal Auditors effective June 16, 2026. M/s. Bhagat & Associates will take over as Statutory Auditors, while M/s. J. M. Raval & Co. has been appointed as Internal Auditor for a five-year term through FY 2030-31. The changes follow the resignation of the previous auditors, which the company attributes to administrative restructuring aimed at improving logistical efficiency with local Ahmedabad-based firms. The outgoing auditors have confirmed there are no professional concerns regarding their resignation.

• M/s. Bhagat & Associates appointed as Statutory Auditor effective June 16, 2026, subject to shareholder approval.
• M/s. J. M. Raval & Co. appointed as Internal Auditor for a 5-year tenure from FY 2026-27 to FY 2030-31.
• Resignation of M/s. Gautam N Associates (Statutory) and M/s. Raj Shah & Co. (Internal) effective June 15, 2026.
• The transition is cited as an administrative move to facilitate closer local coordination with auditors based near the company's registered office.